175 related articles for article (PubMed ID: 33658550)
1. Cryptic-site binding mechanism of medium-sized Bcl-xL inhibiting compounds elucidated by McMD-based dynamic docking simulations.
Bekker GJ; Fukuda I; Higo J; Fukunishi Y; Kamiya N
Sci Rep; 2021 Mar; 11(1):5046. PubMed ID: 33658550
[TBL] [Abstract][Full Text] [Related]
2. Structure-Guided Development of Potent Benzoylurea Inhibitors of BCL-X
Roy MJ; Vom A; Okamoto T; Smith BJ; Birkinshaw RW; Yang H; Abdo H; White CA; Segal D; Huang DCS; Baell JB; Colman PM; Czabotar PE; Lessene G
J Med Chem; 2021 May; 64(9):5447-5469. PubMed ID: 33904752
[TBL] [Abstract][Full Text] [Related]
3. Multiple ligand simultaneous docking: orchestrated dancing of ligands in binding sites of protein.
Li H; Li C
J Comput Chem; 2010 Jul; 31(10):2014-22. PubMed ID: 20166125
[TBL] [Abstract][Full Text] [Related]
4. Advancing the field of computational drug design using multicanonical molecular dynamics-based dynamic docking.
Bekker GJ; Kamiya N
Biophys Rev; 2022 Dec; 14(6):1349-1358. PubMed ID: 36659995
[TBL] [Abstract][Full Text] [Related]
5. Dynamic Docking Using Multicanonical Molecular Dynamics: Simulating Complex Formation at the Atomistic Level.
Bekker GJ; Kamiya N
Methods Mol Biol; 2021; 2266():187-202. PubMed ID: 33759128
[TBL] [Abstract][Full Text] [Related]
6. Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family.
Lee EF; Czabotar PE; Smith BJ; Deshayes K; Zobel K; Colman PM; Fairlie WD
Cell Death Differ; 2007 Sep; 14(9):1711-3. PubMed ID: 17572662
[No Abstract] [Full Text] [Related]
7. Molecular dynamics study of small molecule inhibitors of the Bcl-2 family.
Acoca S; Cui Q; Shore GC; Purisima EO
Proteins; 2011 Sep; 79(9):2624-36. PubMed ID: 21721047
[TBL] [Abstract][Full Text] [Related]
8. Exploring the conformational and binding properties of unphosphorylated/phosphorylated monomeric and trimeric Bcl-2 through docking and molecular dynamics simulations.
Zacarías-Lara OJ; Correa-Basurto J; Bello M
Biopolymers; 2016 Jul; 105(7):393-413. PubMed ID: 27016043
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Bcl-xL prevents pro-death actions of ΔN-Bcl-xL at the mitochondrial inner membrane during glutamate excitotoxicity.
Park HA; Licznerski P; Mnatsakanyan N; Niu Y; Sacchetti S; Wu J; Polster BM; Alavian KN; Jonas EA
Cell Death Differ; 2017 Nov; 24(11):1963-1974. PubMed ID: 28777375
[TBL] [Abstract][Full Text] [Related]
10. Conformational changes in Bcl-2 pro-survival proteins determine their capacity to bind ligands.
Lee EF; Czabotar PE; Yang H; Sleebs BE; Lessene G; Colman PM; Smith BJ; Fairlie WD
J Biol Chem; 2009 Oct; 284(44):30508-17. PubMed ID: 19726685
[TBL] [Abstract][Full Text] [Related]
11. Exploring the selectivity of inhibitor complexes with Bcl-2 and Bcl-XL: A molecular dynamics simulation approach.
Wakui N; Yoshino R; Yasuo N; Ohue M; Sekijima M
J Mol Graph Model; 2018 Jan; 79():166-174. PubMed ID: 29197725
[TBL] [Abstract][Full Text] [Related]
12. A novel mechanism of irinotecan targeting MDM2 and Bcl-xL.
Lee B; Min JA; Nashed A; Lee SO; Yoo JC; Chi SW; Yi GS
Biochem Biophys Res Commun; 2019 Jun; 514(2):518-523. PubMed ID: 31056264
[TBL] [Abstract][Full Text] [Related]
13. Accurate Binding Configuration Prediction of a G-Protein-Coupled Receptor to Its Antagonist Using Multicanonical Molecular Dynamics-Based Dynamic Docking.
Bekker GJ; Araki M; Oshima K; Okuno Y; Kamiya N
J Chem Inf Model; 2021 Oct; 61(10):5161-5171. PubMed ID: 34549581
[TBL] [Abstract][Full Text] [Related]
14. Behavior of solvent-exposed hydrophobic groove in the anti-apoptotic Bcl-XL protein: clues for its ability to bind diverse BH3 ligands from MD simulations.
Lama D; Modi V; Sankararamakrishnan R
PLoS One; 2013; 8(2):e54397. PubMed ID: 23468841
[TBL] [Abstract][Full Text] [Related]
15. Mutual induced-fit mechanism drives binding between intrinsically disordered Bim and cryptic binding site of Bcl-xL.
Bekker GJ; Araki M; Oshima K; Okuno Y; Kamiya N
Commun Biol; 2023 Mar; 6(1):349. PubMed ID: 36997643
[TBL] [Abstract][Full Text] [Related]
16. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.
Rooswinkel RW; van de Kooij B; Verheij M; Borst J
Cell Death Dis; 2012 Aug; 3(8):e366. PubMed ID: 22875003
[TBL] [Abstract][Full Text] [Related]
17. Exhaustive search of the configurational space of heat-shock protein 90 with its inhibitor by multicanonical molecular dynamics based dynamic docking.
Bekker GJ; Araki M; Oshima K; Okuno Y; Kamiya N
J Comput Chem; 2020 Jun; 41(17):1606-1615. PubMed ID: 32267975
[TBL] [Abstract][Full Text] [Related]
18. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
19. N-Terminal-Driven Binding Mechanism of an Antigen Peptide to Human Leukocyte Antigen-A*2402 Elucidated by Multicanonical Molecular Dynamic-Based Dynamic Docking and Path Sampling Simulations.
Bekker GJ; Kamiya N
J Phys Chem B; 2021 Dec; 125(49):13376-13384. PubMed ID: 34856806
[TBL] [Abstract][Full Text] [Related]
20. Structure-Based Analysis of Cryptic-Site Opening.
Sun Z; Wakefield AE; Kolossvary I; Beglov D; Vajda S
Structure; 2020 Feb; 28(2):223-235.e2. PubMed ID: 31810712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
